Nevertheless, the use of GLP‐1 receptor agonists is not without risks; GLP‐1‐based therapies have been notoriously linked to gastrointestinal side effects, including nausea, vomiting, and diarrhea, which may complicate gastrointestinal symptoms in patients with COVID‐19.22 The gene discussed is GLP1R; the disease is COVID-19.